LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.…
LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Split On VIZZ
LENZ Therapeutics (NASDAQ: LENZ) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 40 employees.
The shares were at 2.965 USD on 20 November 2026, down 87.1% over 52 weeks. Its 52-week range is 2.800 USD to 32.13 USD: the price is 90.8% below the high and 5.9% above the low.
Its market capitalisation is 93.16M USD.
LENZ Therapeutics reports return on equity of -28.9% and revenue down 72.9% year over year.
It holds more cash than debt, a net cash position of 196.84M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 23 March 2027.